Satellos to Participate in December Investor Conferences

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a clinical-stage biotechnology company dedicated to developing innovative treatments for degenerative muscle diseases, has announced its participation in two significant investor conferences in December 2025. The company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, starting at 12:50 p.m. ET, where a live webcast will also be available for those interested. Following this, on December 11 at 1:10 p.m. ET, Satellos will take part in a panel discussion at the Oppenheimer Movers in Rare Disease Summit, focusing on the topic of polypharmacy in Duchenne Muscular Dystrophy (DMD) and other neuromuscular diseases.

The leadership team at Satellos will also be available for one-on-one meetings during these events, providing investors an opportunity to gain deeper insights into the company’s initiatives. Interested parties can arrange these meetings through Piper Sandler or Oppenheimer representatives or by contacting Satellos directly.

Satellos is at the forefront of drug development aimed at restoring natural muscle repair mechanisms in conditions such as DMD. Their lead candidate, SAT-3247, represents a breakthrough in oral medication designed to replace the necessary signaling molecule (dystrophin) in muscle stem cells, thereby enhancing their ability to repair and regenerate muscle tissue effectively. Currently undergoing clinical development, SAT-3247 aims to provide a disease-modifying treatment for DMD, with the potential for extending therapeutic applications to other muscle-related conditions through the company’s proprietary MyoReGenX™ discovery platform.

For more information on the company and its developments, visit www.satellos.com.

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) is gearing up for critical investor engagements in December, which could significantly impact its market standing as a clinical-stage biotechnology firm focused on treating degenerative muscle diseases. With the company participating in pivotal conferences — the Piper Sandler 37th Annual Healthcare Conference and the Oppenheimer Movers in Rare Disease Summit — this is an opportune moment for investors to closely monitor the developments.

Satellos is at the forefront of innovative treatment strategies, particularly with its lead candidate, SAT-3247, designed to restore muscle repair mechanisms by targeting the AAK1 protein. Given the pressing need for effective therapies in diseases like Duchenne Muscular Dystrophy (DMD), the potential for SAT-3247 to be a game-changer adds to Satellos’s attractiveness as a long-term investment opportunity.

During these conferences, the leadership team plans to present valuable insights and engage in one-on-one meetings with investors. This direct engagement provides an avenue for potential investors to gauge the company’s pipeline and strategic vision. With a dedicated focus on the therapeutic applications of SAT-3247 and the MyoReGenX™ platform for additional drug discovery, the company’s initiatives can significantly enhance shareholder value.

For investors considering building or expanding their positions in Satellos, these conferences signify a critical window for accessing firsthand information and assessing the company's roadmap to commercialization. The growing interest in rare diseases and muscle degenerative disorders could position Satellos favorably among peers, particularly if that momentum translates into robust clinical trial data. By evaluating participation outcomes and management insights from the conferences, investors can make informed decisions regarding potential investment trajectories in Satellos Bioscience.